Samplix

About:

Samplix's Xdrop® technology is a proprietary droplet-based platform designed for single-molecule encapsulation.

Website: https://www.samplix.com/

Top Investors: European Innovation Council, EASME - EU Executive Agency for SMEs, Fjord Capital

Description:

Samplix has developed a proprietary technology - the Xdrop™ technology – for single molecule sample preparation. At the core of the technology is the generation of millions of droplets formed as “water-oil-water”, each droplet constituting a reaction chamber for the handling of single DNA molecules. The Xdrop™ technology comprises both an instrument and related consumables. Samplix enables single DNA molecule sample preparation where today only multi-molecule sample preparation is possible. Among many applications, the Xdrop™ technology allows for targeted enrichment of very large DNA fragments. Samplix addresses customers’ demand for precision, sensitivity and ease of use by overcoming the technical shortcomings of today's technologies.

Total Funding Amount:

12.7M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Herlev, Hovedstaden, Denmark

Founded Date:

2013-01-01

Contact Email:

mjm(AT)samplix.com

Founders:

Marie Mikkelsen

Number of Employees:

11-50

Last Funding Date:

2023-03-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai